// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1

Saland Jeffrey - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Primary hyperoxaluria type 1

N/A

COVID-19 Infection in Renal Transplant Patients

Hussain AzmUl - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Patients with COVID-19 and Kidney Disease: Who Fared Best?

Antonius Micaela - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Renal disease

N/A

Impact of Ethnicity on COVID-19 Infection and Mortality Amongst In-Centre Haemodialysis Patients

Young GregorD - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

A Novel Optimised Approach to Flow Balance and Fluid Removal During Haemodialysis

Komenda Paul - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Within-Patient Relationships Between Ultrafiltration and Fluid Gains in Haemodialysis Patients

Nguyen Mai - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Unique Case of CKD with Multiple Primary Genitourinary Tumors

Arora Shreya - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Osteoarthritis

N/A

Tacrolimus: A Worth-Considering Culprit for Post-Transplant Anaemia Secondary to Parvovirus B19

Aye MyintThu - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

End stage renal disease

cyclosporin A

Combination Treatment of Liver‐Targeted HBVlocked Nucleic Acid Antisense Oligonucleotide and TLR7 Agonist RO7020531 Leads to Prolonged Off‐Treatment Antiviral Effect in The AAV‐HBV Mouse Model

Julie Blaising - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

RO 7020531

Specialist MDT Clinic Improves Transplant Outcomes of High Risk Patients with Alcohol‐related Liver Disease

Michael Ding - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Alcohol‐associated liver disease

N/A

Efficacy Of Obeticholic Acid In Primary Biliary Cholangitis‐Autoimmune Hepatitis Overlap Patients With Persistently Elevated Transaminases Despite Immunosuppression

Alessio Gerussi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

Alkaline phosphatase

The Extracellular Matrix Derived From Human Cirrhotic Liver Strongly Reduces The Anti‐Cancer Immune Response in a 3D Model Of Hepatocellular Carcinoma

Maria Giovanna Vilia - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

A Common Metabolic Switch Controls Hepatocyte and Macrophage Phenotype Modulation in Liver Injury and is Required for Fibrosis

Jack Leslie - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Significant Association of Fibrosis and Hepatocyte Senescence Biomarkers and Cytokine Profile with Liver Stiffness Measurement Amongst Homeless Individuals with Liver Disease in the Community

Ahmed Hashim - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic fibrosis

Hyaluronic acid

Accumulation Of Intrahepatic Triglyceride Is Associated With Increased Intra‐/Extra‐Myocellular Lipid Ratio And Reduced Hepatic Oxidative Phosphorylation In Young, Non‐Diabetic Males

Prarthana Thiagarajan - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Adenosine-5'-triphosphate

Does Reduced Brown Adipose Tissue Activity Underlie Ethnic Variation In Susceptibility to Non‐Alcoholic Fatty Liver Disease (NAFLD)?

Jane Chalmers - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Fatty Liver Disease

N/A

Role of Osteopontin, Cytokeratin K8 and Mircorrna‐122 As Biomarkers for Idiosyncratic Drug‐Induced Liver Injury and Acute Viral Hepatitis

A Cueto-Sanchez - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Drug-induced liver injury

N/A

COVID-19 infection in a patient with life-treatening hypercalcaemia and sickle cell disease

Desiree Seguna - European Congress of Endocrinology (ECE) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Vitamin D deficiency

cholecalciferol

Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

Miklos Toth - European Congress of Endocrinology (ECE) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acromegaly

Pasireotide

High-dose corticosteroid treatment of immunotherapy-induced hypophysitis: A multi-centric, restrospective analysis

Felix Amereller - European Congress of Endocrinology (ECE) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved